Melanotan II (MT-2) lab tests

Seven checks before you trust a Melanotan II (MT-2) certificate

The same seven questions decide whether a certificate of analysis means anything, whichever compound it describes. Six are about the document; the seventh is about what no document can tell you.

1. An independent, batch-matched COA. The certificate must name the batch or lot in your hands, and must come from a laboratory the vendor neither owns nor pays. A specimen certificate from an earlier lot proves nothing about the vial you were sent.
2. HPLC purity, read against a known band. A purity figure is only informative against the distribution for that compound. "Above 98%" is not a claim — the useful question is whether the result sits inside the range the rest of the market reports. How to read HPLC and mass-spec results.
3. Mass-spectrometry identity. HPLC says how much of the sample is one thing; it does not say which thing. Only a mass-spec result establishes identity, and it is the only check that separates compounds a few daltons apart. Contamination is not hypothetical: research-grade custom peptides from two independent commercial suppliers were found to carry contaminating peptides at roughly 1% by weight, enough to produce false-positive results in immunology assays (Clinical and Vaccine Immunology, 2008 — a study of HIV vaccine peptide libraries rather than of any compound on this site).
4. Net content, measured rather than assumed. Purity and quantity are different questions: a vial can be 99.7% pure and still contain two thirds of the labelled mass. Why 10 mg isn't 10 mg.
5. Endotoxin (LAL) on the batch. An absent endotoxin line means the batch was not tested — not that it passed. Endotoxin testing and LAL interpretation.
6. Who ran the test, and what they left off. A laboratory with a record on this compound, named on the certificate, with a verification route back to it. Testing laboratories we track · Red flags in a certificate of analysis.
7. What no test on the vial can establish. A perfect certificate confirms that a vendor sold the correct molecule at the stated quantity. It says nothing about efficacy, dosing, or long-term safety.

Want a vial tested yourself? How to send a peptide for independent HPLC testing.

What melanotan II testing has to rule out — and what it cannot

Melanotan II is a cyclic heptapeptide analogue of α-MSH, Ac-Nle⁴-c[Asp⁵-His⁶-D-Phe⁷-Arg⁸-Trp⁹-Lys¹⁰]-NH₂, CAS 121062-08-6 (PubChem CID 92432), C₅₀H₆₉N₁₅O₉, 1,024.18 g/mol. Its nearest look-alike is PT-141 (bremelanotide), C₅₀H₆₈N₁₄O₁₀ at 1,025.2. The two share an identical backbone and lactam bridge and differ only at the C-terminus — a lysine amide (–NH₂) in melanotan II against a lysine acid (–OH) in bremelanotide — about 1 Da on 1,024. HPLC co-elutes them and nominal-mass MS cannot reliably separate them; high-resolution mass spectrometry or MS/MS fragmentation on the batch can.

Two published analytical studies exist on exactly this discrimination: Mestria et al. (Drug Testing and Analysis, 2021) characterised black-market melanotan II and bremelanotide by LC-HRMS, and Breindahl et al. (Drug Testing and Analysis, 2015) identified and characterised melanotan II products sold illegally online. The direction of the substitution risk is unusual: receiving bremelanotide instead is not the substitution that harms a melanotan II buyer.

On this compound an identity result settles less than usual. The published harms came from correctly identified material — mass spectrometry confirmed the injected substance was melanotan II in a published rhabdomyolysis case — so a certificate that passes every check confirms the vial holds the compound described in the case literature, not that it is safe. A high purity figure is not a safety finding.

• High-resolution MS or MS/MS at 1,024.18 Da, batch-matched, with the instrument type stated. Nominal-mass MS, or HPLC alone, cannot tell melanotan II from bremelanotide at 1,025.2.
• Fill accuracy as its own check: quantity variance in this platform's melanotan II data ran −7.3% to +16% (verified August 2026). Quantitative content testing is the check.
• Endotoxin (LAL) results are mostly absent on melanotan II. FDA's evaluation language flags immunogenicity risk "due to the potential for aggregation or peptide-related impurities."